Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914743 | 0.96 | PDE5A (1.00) | PDE5A | |
| SCHEMBL7684803 | 0.92 | PDE5A (0.84) | PDE5A | |
| SCHEMBL27510101 | 0.90 | PDE5A (0.81) | PDE5A | |
| SCHEMBL6783701 | 0.90 | PDE5A (0.81) | PDE5A | |
| SCHEMBL7983725 | 0.90 | PDE5A (1.00) | PDE5A | |
| SCHEMBL27563557 | 0.90 | PDE5A (0.81) | PDE5A | |
| SCHEMBL27491546 | 0.90 | PDE5A (0.81) | PDE5A | |
| SCHEMBL7686667 | 0.89 | PDE5A (0.80) | PDE5A | |
| Hydrochloric Acid SCHEMBL6594355 | 0.88 | PDE5A (1.00) | PDE5A | |
| SCHEMBL7073912 | 0.88 | PDE5A (0.83) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288064-B1 | PHOSPHODIESTERASE INHIBITORS; PHTHALAZINE DERIVATIVES | EISAI CO., LTD. (JP) | 2001-09-11 | — | — | US | claimed |
| US-6218392-B1 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, MYOCARDIAL INFARCT AND CHRONIC AND ACUTE CARDIAC FAILURE, PULMONARY HYPERTENSION, ARTERIOSCLEROSIS AND BRONCHIAL ASTHMA | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | claimed |
| EP-0920868-A1 | REMEDY FOR ERECTION FAILURE COMPRISING FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1999-06-09 | — | — | EP | claimed |
| JP-10114657-A | — | — | None | — | — | JP | disclosed |
| CN-1210265-C | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-0722936-B1 | FUSED PYRIDAZINE COMPOUND | EISAI CO LTD (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6288064-B1 | PHOSPHODIESTERASE INHIBITORS; PHTHALAZINE DERIVATIVES | EISAI CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| US-6218392-B1 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, MYOCARDIAL INFARCT AND CHRONIC AND ACUTE CARDIAC FAILURE, PULMONARY HYPERTENSION, ARTERIOSCLEROSIS AND BRONCHIAL ASTHMA | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| CN-1275124-A | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2000-11-29 | — | — | CN | disclosed |
| JP-2000204080-A | PHTHALAZINE DERIVATIVE AND THERAPEUTIC AGENT FOR IMPOTENCE | EISAI CO LTD | 2000-07-25 | — | — | JP | disclosed |
| EP-0920868-A1 | REMEDY FOR ERECTION FAILURE COMPRISING FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5849741-A | Fused pyridazine compounds | EISAI CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| JP-H10114657-A | TREATING AGENT FOR INPOTENTIA ERIGENDI COMPRISING CONDENSED PYRIDAZINE-BASED COMPOUND | EISAI CO LTD | 1998-05-06 | — | — | JP | disclosed |
| EP-0722936-A1 | FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.